---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-017774"
form_type: "8-K"
ticker: "IRWD"
cik: "0001446847"
company_name: "IRONWOOD PHARMACEUTICALS INC"
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:30:00.625733+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ironwood FY2024 revenue $351M, net income positive; apraglutide NDA rolling initiated

## Summary
- Total revenue $90.5M in Q4 and $351.4M for FY2024, down 23% YoY from $442.7M in FY2023.
- GAAP net income $1.8M in FY2024 vs. loss of $1.0B in FY2023 (prior year included impairment).
- Adjusted EBITDA $100.6M for FY2024, a significant improvement from $(884.8)M in FY2023.
- LINZESS prescription demand grew 11% YoY in FY2024; company achieved 2024 financial guidance.
- Rolling NDA submission for apraglutide (SBS) initiated, on track for completion in Q3 2025; OLE data showed 27 patients achieving enteral autonomy.

## SEC filing metadata
- accession: 0001104659-25-017774
- form_type: 8-K
- ticker: IRWD
- cik: 0001446847
- company_name: IRONWOOD PHARMACEUTICALS INC
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/0001104659-25-017774-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446847/000110465925017774/tm257621d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-017774
- JSON: https://secwatch.observer/filing/0001104659-25-017774.json
- Plain text: https://secwatch.observer/filing/0001104659-25-017774.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.